Emma Wright

A very interesting article about the history of #POCT in women's health!

4

Full integration POC rapid diagnostics within the Healthcare systems: Nothing better than having a diagnostic tool near to the patient, that allows fast "Turn Around Time", quicker ER decision making, smoother journey for the patient, saving costs of time, late or early ruling in. POC in critical cases and in cases with critical consequences save costs of admission, transmissions in case of infectious diseases, transportation costs, wrong treatments costs and others. Healthcare policy makers in the Middle East has exerted real effort toward implementing the POC testing in their organizations yet optical cost is still foreseen as a roadblock, however in the way to comple the journey toward better patient quality of life.

22

We were honored to host Professor Tony Young OBE, National Clinical Lead for Innovation at NHS England, as the keynote speaker at our exclusive "Future of Healthcare with AI" luncheon at the House of Lords. In his thought-provoking address, Professor Young shared insight on the critical role of industry collaboration in accelerating AI adoption and how technology can improve patient outcomes. Watch this interview to explore what lies ahead for AI in healthcare 👇 #TechnologyThatDares #HealthcareInnovation #AI

90

2 Comments

Privileged to have had the oppertunity to join this group of experts to discuss how we can improve the outcomes of patients with Peripheral Artery Disease (#PAD) and Critical Limb Threatening Ischaemia (#CLTI), with a specific focus on reducing major limb amputations. #AbbottProud

26

🌟 New Insights from PCCS President 🌟 Discover the future of cardiovascular care with Prof. Raj Thakkar's latest article on integrated working. Learn how a unified approach can transform patient outcomes and optimise NHS resources. Read the full article here: https://lnkd.in/eV2xhsUy #CardiovascularCare #HealthcareInnovation #PCCS

40

We have published a new policy report, which makes the case for greater investment in diagnostic imaging equipment. Dr Stephen Harden, our Vice President for clinical radiology, discusses how equipment and IT will be a major challenge for the next government. Read his blog: https://lnkd.in/eaHGGBmb #Radiology #NHS #Imaging #Diagnostic

31

Missed our panel discussion this week where NHS consultants discussed their 'Top 10 learnings from clinical validation'? Don't worry; we've made the recording available for you to watch on demand. Through our work with more than 20 hospitals covering over 70,000 referrals, we’ve seen that consultant-led clinical validation and prioritisation returns 30% of patients to their GPs with management plans and up to 50% in some specialties, like neurology. We have gained insights into pathway efficiencies and opportunities that NHS consultants shared in our panel discussion earlier this week. You can catch up on the recording below: #ClinicalValidation #ReferralTriage #NHSLeaders #ElectiveRecovery

3

This study will bring not only shorter treatment time, less side effects and better quality of life for prostate patients, it will also built trust in the new method and create a good knowledge base for all users. “Accurate SBRT” for prostate cancer patients is here!

7

🌐 Understanding the NHS Acute Capacity Challenge 🌐 The NHS faces significant challenges in managing acute capacity. Our latest analysis covers: 🔹 Current issues and resource strains 🔹 Potential solutions and innovations 🔹 The role of technology in alleviating pressures https://lnkd.in/gh2nTR7Q

3

As you say good to understand why it works so well

5

We’re excited to confirm that Combat Medical has entered into partnership with the University of Leicester to run a phase 3 trial of our HIVEC® treatment for BCG-unresponsive nonmuscle-invasive bladder cancer (NMIBC) as an alternative to radical cystectomy. HIVEC®-HEAT – HIVEC® (Hyperthermic intravesical mitomycin mEdac) for pAtients with BCG-unresponsive nonmuscle-invasive bladder cancer Trial – will be a multi-centre, single-arm interventional trial across 25 NHS hospitals in the UK. Currently awaiting MRHA approval, and already reviewed by the FDA, it is expected to start recruiting the first of 238 patients in September, with a two-year recruitment period and two-year follow-up. HIVEC®’s use as a safe and well-tolerated bladder-sparing alternative to radical cystectomy in BCG-unresponsive high-risk NMIBC has already been demonstrated in a series of smaller prospective and retrospective studies. A recent analysis has also shown it to be a highly cost-effective therapeutic option, with greater efficacy and at a far lower cost than the FDA-approved pembrolizumab. With 100,000+ treatments already completed in more than 40 countries, we are confident this phase 3 trial will prove that HIVEC® will be a game-changer in the treatment of high-risk, BCG-unresponsive patients, especially at a time of acute BCG shortages worldwide. Funded by Combat Medical, adopted by the National Institute for Health and Care Research and sponsored by the University of Leicester, the investigator-initiated study will be led by Professor Leyshon Griffiths, Associate Professor/Honorary Consultant Urological Surgeon at the University of Leicester & University Hospitals of Leicester NHS Trust. #medicalinnovation #bladdercancer #bladdercancermonth24 #HIVEC #CombatMedical

16

Thinking about an electronic document management system #edms? 💡 Have a read of Restore Digital’s case study and how the digitisation of paper medical records 📖 transformed healthcare in London North West Healthcare NHS Trust 🏥 #MediViewer #Mizaic #EDMS #HealthRecords #DigitalTransformation ⬇️

11

⚡ PRESS RELEASE: New HIVEC®-HEAT Phase 3 trial for bladder cancer could be a game-changer for patients with BCG-unresponsive nonmuscle-invasive #bladdercancer ⚡ Combat Medical has entered into partnership with the University of Leicester to run a phase 3 trial of its HIVEC® treatment for BCG-unresponsive nonmuscle-invasive bladder cancer (NMIBC) as an alternative to radical cystectomy (RC). HIVEC®-HEAT – HIVEC® (H̳yperthermic intravesical mitomycin mE̳dac) for pA̳tients with BCG-unresponsive nonmuscle-invasive bladder cancer T̳rial – will be a multi-centre, single-arm interventional trial across 25 NHS hospitals in the UK. Currently awaiting MRHA approval, and already reviewed by the FDA, it is expected to start recruiting the first of 238 patients in September, with a two-year recruitment period and two-year follow-up. Funded by Combat Medical, adopted by the National Institute for Health and Care Research and sponsored by the University of Leicester, the investigator-initiated study will be led by Professor Leyshon Griffiths, Associate Professor/Honorary Consultant Urological Surgeon at the University of Leicester & University Hospitals of Leicester NHS Trust. Professor Griffiths said: “Why should eligible patients in the UK consider joining the HIVEC®-HEAT trial? Firstly, HIVEC® treatments will recirculate heated mitomycin medac in participants’ bladders at double the concentration (1 mg/mL) compared with standard HIVEC® practice (0.5 mg/mL). Secondly, participants will receive up to 15 HIVEC® treatments over one year – many patients receive less out of trial in UK centres.” #CombatMedical CEO Edward Bruce-White commented: “HIVEC®’s use as a safe and well-tolerated bladder-sparing alternative to radical cystectomy in BCG-unresponsive high-risk NMIBC has already been demonstrated in a series of smaller prospective and retrospective studies. A recent analysis has also shown it to be a highly cost-effective therapeutic option, with greater efficacy and at a far lower cost than the FDA-approved pembrolizumab. With 100,000+ treatments already completed in more than 40 countries, we are confident this phase 3 trial will prove that #HIVEC® will be a game-changer in the treatment of high-risk, BCG-unresponsive patients, especially at a time of acute BCG shortages worldwide.” 573,000 patients are diagnosed with bladder cancer each year, and 70-85% present with NMIBC. Current treatment comprises complete resection of visible tumour, with adjuvant BCG intravesical installation recommended to reduce the risk of recurrence and progression in those with high-risk NMIBC. However, tumours recur in at least 40-50%, with 10-20% progressing to muscle-invasive or metastatic bladder cancer. RC is the standard of care for BCG-unresponsive patients. Performed prior to progression to muscle-invasive bladder cancer, it is curative in 80-90% but associated with a higher degree of morbidity and mortality, with some patients refusing it on quality-of-life grounds.

12

CAN MPOX TRANSMIT VIA BLOOD? UNCLEAR BUT POSSIBLE - See following summary by Roger Dodd and Susan Stramer: “MPXV has some characteristics that imply a potential for transmission by transfusion, although no cases had been reported at the time of writing (September 2022). However, it is appropriate to consider this as a possibility. ”https://lnkd.in/d7i42gkU - Greninger et al paper makes a similar statement about the uncertainty but need for vigilance by blood bankers. https://lnkd.in/d8-HaHNS CAN INTERCEPT INACTIVATE MPOX? - Specific mpox inactivation studies are yet to me made. However, the Dodd and the Greninger papers (and Cerus press release: https://lnkd.in/dZ9Qs4FC) all indicate that INTERCEPT is likely to inactivate mpox because it has been shown effective against Vaccinia virus which is in the same family as mpox. BLOOD BANKERS NEED TO CONTINUE TO BE VIGILANT AS NEW THREATS ARE CONSTANTLY EMERGING - Region Stockholms 'treatment guide' states you are NOT allowed to donate blood if you have in close contact with individuals having been infected by mpox. I.e. mpox impacts blood availability negatively. https://lnkd.in/dg6aVtui #TRIPOD, #PATHOGENINACTIVATION, #SOCIALSTYRELSENNOVEMBERREPORT

14

Important updates for our BSOL Elective Care Gynaecology Service!   We're pleased to share new business updates with our Birmingham & Solihull Elective Care Gynaecology Service! To learn more about the specific changes, please see below.   If you have any questions, please get in touch with us at [email protected]. #NHS #Healthcare #Gynaecology

9

📢 Discover how the NHS can tackle its biggest challenges with better use of patient data! 📖 In Part 1 of our series, Research Manager Georgina Culliford explores the key issues facing health and care in the UK and how a combination of data insights and meaningful public engagement may help drive improvements. #NHS #Healthcare #NHSchallenges #PatientData #PublicEngagement

5

More real-world evidence for lung cancer screening. with the rapid roll-out of lung cancer screening programs globally we see more an more real-world evidence how well it works. This underlines the need to move forward with #lungcancerscreening. One recent publication from Liverpool and London (Michael Davies, Daniel Vulkan, Rhian Gabe, stephen duffy, Professor John Field) is especially remarkable. It gained a lot of attention for showing that #lungcancerscreening can mitigate the negative health effects of socio-economic deprivation. But there is even more interesting data in the publication - I picked a few things that I found worth noticing, attached are graphs with my comments. 1. There is (again) no sign of overdiagnosis. As I explained in previous posts, if you plot the number of diagnosed lung cancers, overdiagnosis would appear as an upward shift (red). This is (again) not the case, so with long-enough follow-up, there is the same number of lung cancers found without screening, just later. No overdiagnosis. Zero. The earlier diagnosis is clearly visible as a left-shift of the graph (green). Very good, one more confirmation. Here the single-screen approach of UKLS is an advantage: We can clearly distinguish between left and upward shift of the curves. If you screening continuously, you couldn't tell. 2. There is reduction of all-cause mortality in the deprived group. Given that the study was neither powered nor designed to measure all-cause mortality (small sample size, only a single CT exam), the expected result would be no visible effect, as we see in the higher-status groups (Q3-Q5, orange and green). However, we see a strong effect in the deprived group. Interestingly, the authors attribute this to improvements in COPD in the screened group - this is a positive effect that so far was not really seen in lung cancer screening studies. Given the limited sample size, this effect must be really strong - looking forward to seeing more on this. 3. My mantra: The mortality reduction of screening is much more than the often-cited 20% from NLST. See the survival curves of screen-detected vs. non-screen detected lung cancers. You have to consider that the real effect with continuous screening is of course even more than here (single round of screening).

103

9 Comments

The recent allocation of additional #funding to the NHS is expected to significantly impact the reduction of waiting times for patients. Below, we outline the key points regarding how this funding will affect NHS waiting lists. In conclusion, the additional funding is set to positively impact NHS waiting times by enhancing capacity and access to care. However, successful implementation will depend on effectively managing demand and ensuring that improvements are sustainable in the long term. #healthcare #primarycare #nhs #funding

4